239 related articles for article (PubMed ID: 23357569)
1. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.
Kimball AB; Pariser D; Yamauchi PS; Menter A; Teller CF; Shi Y; Yong M; Creamer K; Hooper M; Aras G; Kricorian G; Gelfand JM
J Am Acad Dermatol; 2013 May; 68(5):756-64. PubMed ID: 23357569
[TBL] [Abstract][Full Text] [Related]
2. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
[TBL] [Abstract][Full Text] [Related]
3. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
Kimball AB; Rothman KJ; Kricorian G; Pariser D; Yamauchi PS; Menter A; Teller CF; Aras G; Accortt NA; Hooper M; Rice KC; Gelfand JM
J Am Acad Dermatol; 2015 Jan; 72(1):115-22. PubMed ID: 25264239
[TBL] [Abstract][Full Text] [Related]
4. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
5. Long-term etanercept in pediatric patients with plaque psoriasis.
Paller AS; Siegfried EC; Eichenfield LF; Pariser D; Langley RG; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):762-8. PubMed ID: 20605256
[TBL] [Abstract][Full Text] [Related]
6. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
Gottlieb AB; Leonardi CL; Goffe BS; Ortonne JP; van der Kerkhof PC; Zitnik R; Nakanishi A; Jahreis A
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S92-100. PubMed ID: 16488335
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up.
Puig L; Camacho Martínez FM; Gimeno Carpio E; López-Ávila A; García-Calvo C
Dermatology; 2012; 225(3):220-30. PubMed ID: 23235195
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J
J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
10. Intermittent etanercept therapy in pediatric patients with psoriasis.
Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
[TBL] [Abstract][Full Text] [Related]
11. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
[TBL] [Abstract][Full Text] [Related]
12. Etanercept: efficacy and safety.
Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
14. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
15. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.
Menter A; Thaçi D; Papp KA; Wu JJ; Bereswill M; Teixeira HD; Rubant S; Williams DA
J Am Acad Dermatol; 2015 Sep; 73(3):410-9.e6. PubMed ID: 26190240
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
18. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
19. Etanercept use for psoriasis in Taiwan: a case series study.
Chiu HY; Wang TS; Cho YT; Tsai TF
Int J Dermatol; 2013 Jun; 52(6):673-80. PubMed ID: 22348620
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
